Multimodality Treatement in Patients with Clinical Stage IIIA NSCLC.
10.4046/trd.2004.57.6.557
- Author:
Yun Seun LEE
1
;
Pil Soon JANG
;
Hyun Mo KANG
;
Jeung Eyun LEE
;
Sun Jung KWON
;
Jin Yong AN
;
Sung Soo JUNG
;
Ju Ock KIM
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Chungnam National University, Daejon, Korea. sykim@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Multimodality Treatement;
Stage IIIA;
NSCLC;
Induction Chemotherapy
- MeSH:
Chungcheongnam-do;
Disease Progression;
Disulfiram;
Drug Therapy;
Humans;
Induction Chemotherapy;
Lung;
Neoplasm Metastasis;
Patient Selection;
Recurrence;
Survival Rate;
Thorax
- From:Tuberculosis and Respiratory Diseases
2004;57(6):557-566
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To find out effectiveness of multimodality treatments based on induction chemotherapy(CTx) in patients with clinical stage IIIA NSCLC METHODS: From 1997 to 2002, 74 patients with clinical stage IIIA NSCLC underwent induction CTx at the hospital of Chungnam National University. Induction CTx included above two cycles of cisplatin-based regimens(ectoposide, gemcitabine, vinorelbine, or taxol) followed by tumor evaluation. In 30 complete resection group, additional 4500-5000cGy radiotherapy(RTx) was delivered in 15 patients with pathologic nodal metastasis. 29 out of 44 patients who were unresectable disease, refusal of operation, and incomplete resection were followed by 60-70Gy RTx in local treatment. Additional 1-3 cycle CTx were done in case of induction CTx responders in both local treatment groups. RESULTS: Induction CTx response rate were 44.6%(complete remission 1.4% & partial response 43.2%) and there was no difference of response rate by regimens(p=0.506). After induction chemotherapy, only 33 out of resectable 55 ones(including initial resectable 37 patients) were performed by surgical treatment because of 13 refusal of surgery by themselves and 9 poor predicted reserve lung function. There were 30(40.5%) patients with complete resection, 2(2.6%) persons with incomplete resection, and 1(1.3%) person with open & closure. Response rate in 27 ones with chest RTx out of non-operation group was 4.8% CR and 11.9% PR. In complete resection group, relapse free interval was 13.6 months and 2 year recur rate was 52%. In non-complete resection(incomplete resection or non-operation) group, disease progression free interval was 11.2 months and 2 year disease progression rate was 66.7%. Median survival time of induction CTx 74 patients with IIIA NSCLC was 25.1months. When compared complete resection group with non-complete resection group, the median survival time was 31.7 and 23.4months(p=0.024) and the 2-year overall survival rate was 80% and 41% . In the complete resection group, adjuvant postoperative RTx subgroup significantly improved the 2-year local control rate(0% vs. 40%, p= 0.007) but did not significantly improve overall survival(32.2months vs. 34.9months, p=0.48). CONCLUSION: Induction CTx is a possible method in the multimodality treatments, especially followed by complete resection, but overall survival by any local treatment(surgical resection or RTx) was low. Additional studies should be needed to analysis data for appropriate patient selection, new chemotherapy regimens and the time when should RTx be initiated.
